Redhill Biopharma PE Ratio 2013-2020 | RDHL

Current and historical p/e ratio for Redhill Biopharma (RDHL) from 2013 to 2020. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Redhill Biopharma PE ratio as of June 05, 2020 is 0.00.
Redhill Biopharma PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2020-06-05 6.82 0.00
2020-03-31 4.53 $-0.98 0.00
2019-12-31 6.07 $-1.33 0.00
2019-09-30 7.04 $-1.37 0.00
2019-06-30 6.50 $-1.47 0.00
2019-03-31 8.31 $-1.61 0.00
2018-12-31 5.55 $-1.76 0.00
2018-09-30 8.83 $-1.92 0.00
2018-06-30 8.53 $-2.42 0.00
2018-03-31 5.15 $-2.50 0.00
2017-12-31 5.14 $-2.50 0.00
2017-09-30 10.81 $-2.70 0.00
2017-06-30 8.62 $-2.50 0.00
2017-03-31 9.59 $-2.50 0.00
2016-12-31 10.46 $-2.43 0.00
2016-09-30 13.89 $-2.23 0.00
2016-06-30 10.87 $-1.93 0.00
2016-03-31 12.25 $-1.99 0.00
2015-12-31 12.88 $-2.06 0.00
2015-09-30 12.91 $-2.16 0.00
2015-06-30 17.61 $-2.26 0.00
2015-03-31 14.55 $-2.12 0.00
2014-12-31 13.33 $-1.23 0.00
2014-09-30 13.17 $-1.13 0.00
2014-06-30 17.49 $-1.06 0.00
2014-03-31 14.09 $-0.94 0.00
2013-12-31 11.80 $-1.63 0.00
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.241B $0.006B
RedHill Biopharma Ltd. is a specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases. RedHill promotes the gastrointestinal drug Aemcolo(TM) in the U.S. and is planning to launch Talicia(TM) in the U.S. for the treatment of Helicobacter pylori (H. pylori) infection in adults. RedHill's key clinical late-stage development programs include: RHB-104, with positive results from a first Phase 3 study for Crohn's disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; RHB-102 (Bekinda(TM)), for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; ABC294640 (Yeliva(TM)), a first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 2a study for cholangiocarcinoma; RHB-106, an encapsulated bowel preparation, and RHB-107.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $66.971B 38.01
Takeda Pharmaceutical (TAK) Japan $58.578B 10.27
Astellas Pharma (ALPMY) Japan $32.167B 16.07
Eisai (ESALY) Japan $23.844B 44.42
UCB SA (UCBJF) Belgium $19.723B 0.00
Merck (MKGAF) Germany $15.251B 20.00
Grifols, S.A (GRFS) Spain $13.765B 17.11
Catalent (CTLT) United States $11.571B 44.73
Neurocrine Biosciences (NBIX) United States $10.759B 49.73
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $9.945B 0.00
Ono Pharmaceutical (OPHLF) Japan $9.254B 19.78
Ionis Pharmaceuticals (IONS) United States $8.019B 42.64
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $7.270B 0.00
Orion OYJ (ORINY) Finland $6.978B 31.27
IPSEN SA ADR (IPSEY) France $6.836B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.676B 10.69
United Therapeutics (UTHR) United States $5.442B 10.31
STADA ARZNEIMI (STDAF) Germany $4.916B 0.00
Hypermarcas (HYPMY) Brazil $4.362B 13.27
Evotec AG (EVTCY) Germany $4.119B 66.40
Nektar Therapeutics (NKTR) United States $3.964B 0.00
ChemoCentryx (CCXI) United States $3.711B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $3.467B 378.56
PTC Therapeutics (PTCT) United States $3.174B 0.00
FibroGen (FGEN) United States $2.908B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.603B 10.70
Cronos Group (CRON) Canada $2.302B 66.00
Pacira BioSciences (PCRX) United States $2.045B 41.85
Sage Therapeutics (SAGE) United States $1.880B 0.00
USANA Health Sciences (USNA) United States $1.805B 18.52
Heron Therapeutics (HRTX) United States $1.748B 0.00
Xencor (XNCR) United States $1.710B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.686B 0.00
Zogenix (ZGNX) United States $1.659B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.630B 0.00
Corcept Therapeutics (CORT) United States $1.626B 16.13
Ironwood Pharmaceuticals (IRWD) United States $1.584B 12.12
Akebia Therapeutics (AKBA) United States $1.557B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.482B 15.97
Portola Pharmaceuticals (PTLA) United States $1.406B 0.00
Karyopharm Therapeutics (KPTI) United States $1.296B 0.00
Esperion Therapeutics (ESPR) United States $1.252B 0.00
CLINIGEN GP (CLIGF) United Kingdom $1.224B 0.00
Tilray (TLRY) Canada $1.184B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.015B 45.29
Endo (ENDP) Ireland $0.972B 1.51
Translate Bio (TBIO) United States $0.935B 0.00
ImmunoGen (IMGN) United States $0.794B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.736B 0.00
Indivior (INVVY) United States $0.718B 8.91
Aerie Pharmaceuticals (AERI) United States $0.700B 0.00
Collegium Pharmaceutical (COLL) United States $0.676B 0.00
Molecular Templates (MTEM) United States $0.651B 0.00
Radius Health (RDUS) United States $0.616B 0.00
Ardelyx (ARDX) United States $0.615B 0.00
Trillium Therapeutics (TRIL) Canada $0.597B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.525B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.499B 0.00
Innate Pharma SA (IPHYF) France $0.489B 0.00
Siga Technologies (SIGA) United States $0.483B 0.00
Flexion Therapeutics (FLXN) United States $0.474B 0.00
DURECT (DRRX) United States $0.472B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.464B 11.21
Organogenesis Holdings (ORGO) United States $0.461B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.441B 17.21
Harpoon Therapeutics (HARP) United States $0.429B 0.00
MEI Pharma (MEIP) United States $0.395B 0.00
Ocular Therapeutix (OCUL) United States $0.386B 0.00
Calithera Biosciences (CALA) United States $0.374B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.359B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.326B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.324B 0.00
TherapeuticsMD (TXMD) United States $0.321B 0.00
Lannett Co Inc (LCI) United States $0.320B 7.02
Avadel Pharmaceuticals (AVDL) Ireland $0.314B 0.00
Concert Pharmaceuticals (CNCE) United States $0.278B 0.00
CASI Pharmaceuticals (CASI) United States $0.269B 0.00
Rafael Holdings (RFL) United States $0.269B 0.00
OptiNose (OPTN) United States $0.246B 0.00
Jounce Therapeutics (JNCE) United States $0.221B 5.27
KalVista Pharmaceuticals (KALV) United States $0.209B 0.00
PROFOUND MEDICL (PROF) Canada $0.207B 0.00
Nature's Sunshine Products (NATR) United States $0.193B 25.44
Xeris Pharmaceuticals (XERS) United States $0.182B 0.00
Taiwan Liposome (TLC) Taiwan $0.180B 0.00
VAXART, INC (VXRT) United States $0.180B 0.00
IMV INC (IMV) Canada $0.178B 0.00
Aquestive Therapeutics (AQST) United States $0.173B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.171B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.148B 0.00
Altimmune (ALT) United States $0.117B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.117B 0.00
Recro Pharma (REPH) United States $0.117B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.113B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.109B 0.00
Champions Oncology (CSBR) United States $0.107B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.104B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.097B 0.00
Otonomy (OTIC) United States $0.091B 0.00
Sundial Growers (SNDL) Canada $0.088B 0.00
SCYNEXIS (SCYX) United States $0.085B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.081B 0.00
CTI BioPharma (CTIC) United States $0.080B 0.00
Onconova Therapeutics (ONTX) United States $0.080B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.076B 0.00
CV Sciences (CVSI) United States $0.075B 0.00
Hemispherx BioPharma (AIM) United States $0.074B 0.00
Heat Biologics (HTBX) United States $0.073B 0.00
Nivalis Therapeutics (ALPN) United States $0.072B 0.00
Aclaris Therapeutics (ACRS) United States $0.060B 0.00
MediWound (MDWD) Israel $0.057B 0.00
RENEURON GP (RNUGF) United Kingdom $0.056B 0.00
Biomerica (BMRA) United States $0.053B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.053B 31.55
Infinity Pharmaceuticals (INFI) United States $0.052B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.050B 106.36
Natural Alternatives (NAII) United States $0.049B 0.00
ElectroCore (ECOR) United States $0.049B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.048B 0.00
IsoRay (ISR) United States $0.048B 0.00
GTx (ONCT) United States $0.046B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.044B 0.00
PolarityTE (PTE) United States $0.044B 0.00
Lipocine (LPCN) United States $0.043B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.042B 0.00
Forward Pharma (FWP) Denmark $0.040B 0.00
Addex Therapeutics (ADXN) Switzerland $0.040B 0.00
Mannatechorporated (MTEX) United States $0.039B 7.47
Adamis Pharmaceuticals (ADMP) United States $0.039B 0.00
Neos Therapeutics (NEOS) United States $0.039B 0.00
Novan (NOVN) United States $0.035B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.034B 0.00
AgeX Therapeutics (AGE) United States $0.034B 0.00
Jaguar Animal Health (JAGX) United States $0.028B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.024B 0.00
India Globalization Capital (IGC) United States $0.024B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.023B 0.00
Iterum Therapeutics (ITRM) Ireland $0.022B 0.00
Bio-Path Holdings (BPTH) United States $0.020B 0.00
Flex Pharma (SLRX) United States $0.018B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.018B 0.00
Regulus Therapeutics (RGLS) United States $0.017B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.017B 0.00
Can-Fite Biopharma (CANF) Israel $0.017B 0.00
ProPhase Labs (PRPH) United States $0.016B 0.00
Shineco (TYHT) China $0.012B 0.00
Cyanotech (CYAN) United States $0.012B 0.00
China SXT Pharmaceuticals (SXTC) China $0.012B 0.00
RXi Pharmaceuticals (PHIO) United States $0.012B 0.00
Vical (BBI) United States $0.011B 0.00
HANCOCK JAFFE (HJLI) United States $0.007B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.007B 0.00
Midatech Pharma (MTP) United Kingdom $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00